Self-Reported Eczema Valid for Detecting Atopic Dermatitis

This article originally appeared here.
Share this content:
Self-Reported Eczema Valid for Detecting Atopic Dermatitis
Self-Reported Eczema Valid for Detecting Atopic Dermatitis

MONDAY, July 27, 2015 (HealthDay News) -- Self- and caregiver-reported history of eczema is valid for identifying atopic dermatitis (AD), according to a study published online July 17 in the British Journal of Dermatology.

Jonathan I. Silverberg, M.D., Ph.D., M.P.H., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues performed a prospective multicenter dermatology practice-based study at three sites to examine the validity of caregiver- and self-reported ever and one-year history of eczema. Unselected patients were surveyed with questionnaires. Seven hundred eighty-two patients were then assessed by expert dermatologists.

The researchers found that, compared with a physician diagnosis of AD at that visit, caregiver-reported one-year history of childhood eczema had a sensitivity, specificity, and positive predictive value (PPV) of 0.70, 0.96, and 0.87, respectively. The corresponding values were 0.70, 0.95, and 0.76 for self-reported one-year history of adult eczema. Ever-history of caregiver- and self-reported eczema had high specificity (0.89 and 0.97, respectively) and PPV (0.81 and 0.91, respectively), with high sensitivity in children but not adults (0.83 versus 0.43).

"Self- and caregiver-reported diagnosis of eczema ever or in the past year based on a single question demonstrates sufficient validity for the epidemiological study of AD," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »